Biogen Idec News

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Cambridge biotechnology company Biogen Idec Inc. said two directors will be leaving its board.

Company and People Notes: PhRMA adds biopharm members; Dow spins off expression technology; and more.

Biogen Idec has raised its unsolicited bid for Facet Biotech from $14.50 per share to $17.50 per share.

Buyout fever heated up in the local biotechnology sector yesterday, with a pair of privately held Cambridge biosciences companies linking up with out-of-state partners in two separate deals.

December 7, 2009 - Biogen Idec today announced that its oral compound BG-12 achieved key milestones in clinical trials for multiple sclerosis and rheumatoid arthritis .

Biogen Idec Inc. said Thursday it raised its offer for Facet Biotech Corp. to $17.50 per share from $14.50 per share, valuing Facet at a total of $493 million.

Receptos, Inc., a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing.

One of Biogen Idec Inc. 's largest investors is criticizing chief executive James Mullen's compensation package and other corporate spending initiatives in an effort to goad the company into boosting its stock performance.

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.-- --Genentech, Inc., a wholly-owned member of the Roche Group , and Biogen Idec announced today that the U.S. Food and Drug Administration issued a complete response on the companies' applications for Rituxan plus fludarabine and cyclophosphamide for the treatment of people with previously untreated ...

Ireland's Elan and U.S. drugmaker Biogen Idec have amended the label of their multiple sclerosis drug Tysabri to reflect the increased risk of contracting a potentially deadly brain infection, Elan said in a statement on Saturday.

Biogen Idec By Jefferies & Company WE ARE UPGRADING Biogen to Buy from Hold on valuation; maintaining our price target of $50, about 19% upside to current share price.

"We are executing on our development programs while remaining vigilant on cost containment and expense management," said Faheem Hasnain, president and chief executive officer of Facet Biotech.

Our analysts have issued complimentary analysis on the following six companies: New York Community Bancorp Inc.

Unsubstantiated whisperings about Biogen Idec and its controversial multiple sclerosis drug took an ugly turn to the truth on Thursday when European regulators disclosedA another new case of progressive multifocal leukoencephalopathy , a serious brain infection known as PML, in a relapsed MS patient receiving Tysabri infusions.

Today the EMEA, the European equivalent of the U.S. Food and Drug Administration, released a statement indicating that one of its advisory committees was launching a review of the risks and benefits of Tysabri in light of 23 confirmed cases of PML that it says have occurred since the drug has been on the market.

Thirteen was a good number for Biogen Idec and Elan . Twenty-three? Not so much.

Biogen Idec 's key multiple sclerosis drug is in the news again, as the European Medicines Agency has started a safety review of Tysabri , citing more confirmed cases of a rare - but potentially fatal - viral infection of the brain, called progressive multifocal leukoencephalopathy , previously linked to the drug.

Shares of Biogen Idec fell Friday as European regulators investigate reports of 23 cases of Tysabri patients with a potentially fatal brain infection.

Total revenue rose 6% thanks to Tysabri's slow but steady growth; Biogen Idec spilled the beans on that earlier in the week.